Ectosomes, New Biomarkers of Tau Pathology?

Alzheimer Disease Clinical Trial

— ECTAUSOME  

Official title:

Ectosomes, New Biomarkers of Tau Pathology?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03381482
• Other study ID #: 2016_59
• Secondary ID: 2017-A01715-48
• Status: Recruiting
• Start date: December 20, 2017
• Est. completion date: December 2023

Study information

• Verified date: February 2023
• Source: University Hospital, Lille
• Contact: Vincent DERAMECOURT, MD,PhD
• Phone: 320446021
• Email: vincent.deramecourt[@]chru-lille.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In Alzheimer's disease (AD), neurofibrillary degeneration (NFD) is characterized by the intraneuronal aggregation of Tau proteins. The pathology progresses through a hierarchical pathway that may be associated with the intercellular transmission of pathology as demonstrated in our rat models. This transmission implies that Tau is actively secreted and may participate to the first steps of Tau pathology spreading. It is demonstrated in cell lines and animal models (rodents and non-human primates) that Tau is secreted not only in free forms but also in extracellular vesicles. If Tau is found in biological fluids before neuronal death it may represent an early marker of the NFD and will also define therapeutically targets. In this context, the aim is now to transfer this knowledge in humans and to decipher the nature of Tau secreted in plasma and cerebrospinal fluids collected from healthy controls to AD patients, and to decipher if the presence of tau inside vesicles is influenced by the pathology.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• Subjects able to undergo a lumbar puncture;
• Subjects who have a partner who will be required for driving back the subject after the lumbar punction for safety reasons (not required for control subjects);
• Subjects (or the study partner for group 5) capable of and willing to comply with the protocol and to give their written informed consents after having received and understood the subject information. According to the legal protection or the mental capacities of the subject, he/she will be accompanied by him/her legally acceptable representative during this procedure;
• Blood coagulation testing
• Subjects registered with the French Social Security, in agreement with the French law on biomedical experimentation. Group 1: controls
• absence of cognitive complaint
• absence of significant cognitive impairment: MMSE>27
• Negative ApoE4 status (e 4-/ e 4-) No family history of AD at first degree Group 2:

asymptomatic cases with high risk to develop AD

• absence of cognitive complaint
• absence of significant cognitive impairment : MMSE>27
• known ApoE4 status or family history of AD at first degree Group 3: cases with isolated cognitive complaint
• presence of a cognitive complaint
• absence of cognitive impairment assessed by MMSE>27 and standard neuropsychological examination (performed < 1 year) Group 4: prodromal AD according to the 2007 criteria (Dubois et al., 2007)
• progressive and significant episodic memory impairment >6 months
• And at least one of the following: medial temporal atrophy of brain MRI / low Ab42 and increased total and phosphorylated Tau protein in the CSF/ bilateral temporoparietal hypometabolism on brain FDG-PET/ positive amyloid brain PET if available
• exclusion of any differential diagnoses Group 5: Mild to moderate probable AD-type dementia according to the NIA 2011 criteria
• progressive and significant cognitive decline >6 months
• amnestic or any other predominant clinical presentation
• exclusion of any differential diagnoses
• MMSE between 15 and 26 (inclusive)

Exclusion Criteria:

• Subjects with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load;

Associated Illnesses or conditions:

• Subjects with other neurodegenerative disease such as fronto-temporal dementia (FTD), Lewy body dementia and Parkinson's disease;
• Subjects with other serious neurological disorder such as brain tumour, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study;
• Subjects with demyelinating diseases of the peripheral nervous system such as Guillain-Barre Syndrome;

Biological exclusion criteria:

• Subjects with known active Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV);
• Subjects with clinical or significant laboratory abnormalities, in the judgment of the investigator;

Others:

• Subjects with excessive alcohol intake or drug abuse, in the judgment of the investigator;
• Subjects who have contraindications to perform a lumbar puncture;
• Subjects who, in the opinion of the Investigator, have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial (for example, being impossible to contact in case of emergency).

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Diagnostic Test:
• CSF drawing during spinal anaesthesia
4mL of CSF by lumbar puncture
• Fasting blood sample
6x5 mL of fasting blood sample
• Lumbar puncture
10 mL of CSF by lumbar puncture

Locations

Country	Name	City	State
France	Hôpital Roger Salengro, CHRU	Lille

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence of Tau in extracellular vesicles in CSF	Tau will be measured by ELISA in extracellular vesicles and the presence of Tau in extracellular vesicles will considered positive if the concentration of Tau is superior to the sensitivity threshold of the antibody used.	Baseline
Secondary	The ratio of free Tau/vesicular Tau for all groups will be assessed with samples obtained during the visit.	Tau will be measured by ELISA (concentration of Tau in pg/mL) and using the Nanosight technology (% of vesicles containing Tau). Results will be expressed either in percentage or in concentration (ie concentration of free Tau/concentration of vesicular Tau; % of free Tau/% of vesicular Tau).	Baseline
Secondary	The presence of clusters of the epigenetic markers H3K9me3 in nuclei of peripheral blood mononuclear cells for all groups will be assessed with samples obtained during the visit.	The H3K9m3 marker will be revealed by immunodetection and revealed by fluorescence. The presence of one cluster of H3K9m3 will be considered as positive. Results will be expressed in % of cells with clusters.	Baseline